BIT Capital GmbH Buys 3,347 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

BIT Capital GmbH grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 4.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,921 shares of the biotechnology company's stock after purchasing an additional 3,347 shares during the quarter. Blueprint Medicines comprises approximately 0.5% of BIT Capital GmbH's portfolio, making the stock its 28th biggest holding. BIT Capital GmbH owned 0.12% of Blueprint Medicines worth $6,883,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Blueprint Medicines in the third quarter worth $475,000. Advisors Asset Management Inc. grew its holdings in shares of Blueprint Medicines by 17.6% during the third quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company's stock worth $467,000 after purchasing an additional 756 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Blueprint Medicines by 9.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company's stock worth $55,244,000 after purchasing an additional 50,736 shares during the last quarter. Citigroup Inc. lifted its stake in shares of Blueprint Medicines by 19.3% in the 3rd quarter. Citigroup Inc. now owns 143,441 shares of the biotechnology company's stock valued at $13,268,000 after acquiring an additional 23,189 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Blueprint Medicines during the 3rd quarter valued at about $108,000.

Remove Ads

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Morgan Stanley started coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective for the company. JPMorgan Chase & Co. increased their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. StockNews.com lowered shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday, March 18th. They issued an "outperform" rating for the company. Finally, Stephens restated an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $124.95.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,496,700. This trade represents a 13.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the sale, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,608 shares of company stock valued at $3,319,587 over the last 90 days. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

NASDAQ BPMC traded down $1.36 during trading hours on Monday, hitting $87.37. 219,766 shares of the company's stock traded hands, compared to its average volume of 994,776. Blueprint Medicines Co. has a 52 week low of $80.68 and a 52 week high of $121.90. The firm has a market capitalization of $5.58 billion, a P/E ratio of -80.60 and a beta of 0.58. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. The business's fifty day moving average price is $98.13 and its two-hundred day moving average price is $94.04.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.